Growth During Tocilizumab Therapy for Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From a Phase III Clinical Trial

Yearbook of Paediatric Endocrinology
doi 10.1530/ey.16.9.15
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Bioscientifica

Related search

Neutropenia During Tocilizumab Treatment Is Not Associated With Infection Risk in Systemic or Polyarticular-Course Juvenile Idiopathic Arthritis

Journal of Rheumatology
RheumatologyAllergyImmunology
2019English

Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis

2020English

Tocilizumab for Juvenile Idiopathic Arthritis: A Single-Center Case Series

Sao Paulo Medical Journal
Medicine
2019English

Tocilizumab in Patients With Anti-TNF Refractory Juvenile Idiopathic Arthritis-Associated Uveitis (APTITUDE): A Multicentre, Single-Arm, Phase 2 Trial

Lancet Rheumatology, The
RheumatologyAllergyImmunology
2020English

Polyarticular Juvenile Idiopathic Arthritis &Ndash; Epidemiology and Management Approaches

Clinical Epidemiology
Epidemiology
2014English

Polyarticular Juvenile Idiopathic Arthritis (pJIA): Clinical and Serologic Predictors of Inactive Disease (ID)

Pediatric Rheumatology
ImmunologyPediatricsRheumatologyAllergyPerinatologyChild Health
2014English

Biological Disease-Modifying Antirheumatic Drugs in Juvenile Idiopathic Arthritis of Polyarticular Course, Enthesitis-Related Arthritis, and Psoriatic Arthritis: A Consensus Statement

2020English

Juvenile Idiopathic Arthritis With Rice Bodies in a 2-Year-Old Girl

Journal of Pediatrics
Child HealthPediatricsPerinatology
2016English

7.4 Improvements in Individual Disease Components Are Sustained With Long-Term Adalimumab Therapy for Polyarticular Juvenile Idiopathic Arthritis

Pediatric Rheumatology
ImmunologyPediatricsRheumatologyAllergyPerinatologyChild Health
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy